dietUAT: Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules

Sponsor
Icahn School of Medicine at Mount Sinai (Other)
Overall Status
Completed
CT.gov ID
NCT00474396
Collaborator
(none)
59
18

Study Details

Study Description

Brief Summary

The purpose of the study is to determine whether low fat dairy diet reduces serum uric acid levels.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Low fat dairy diet
N/A

Detailed Description

Uric acid plays a role not only in the pathogenesis of gout but is also a predictor of cardiovascular disease, hypertension and renal disease in man. We have identified the human urate ion channel transporter (hUAT), located in the proximal convoluted tubule of the kidney that is involved in both the secretion and reabsorption of urate across the tubule. This channel has a unique lectin binding site that in in-vitro studies, has been found to be modulated by glucose, galactose and lactose. We have also identified a mutation (G/A polymorphism) in our laboratory, that in in-vitro studies has demonstrated diminished hUAT channel activity. Cross-sectional studies have earlier shown that uric acid levels vary with serum glucose levels. Studies have also reported that a low-fat dairy diet reduces the incidence of gout, while others have shown that this diet reduces blood pressure significantly when compared with a non-dairy diet. We hypothesize that the effect of blood glucose levels in lowering uric acid levels is through the regulation of hUAT channel activity. We also hypothesize that a low-fat dairy diet reduces serum uric acid levels through hUAT regulation leading to a decrease in the incidence of gout and a reduction in blood pressure levels. In our proposed randomized, controlled, cross-over trial in healthy adult volunteers, we aim to study the effect of a low-fat dairy diet and a non-dairy diet on serum uric acid levels, the renal fractional excretion of uric acid and blood pressure. We will also study the effect of an acute intravenous infusion of glucose on these parameters. DNA analysis for hUAT mutations of study subjects will be done to assess if there is a blunted response of hUAT activity in subjects with the polymorphism as compared to normal individuals.

Study Design

Study Type:
Interventional
Actual Enrollment :
59 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Basic Science
Official Title:
Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules
Study Start Date :
Apr 1, 2005
Actual Study Completion Date :
Oct 1, 2006

Outcome Measures

Primary Outcome Measures

  1. Lowering of serum uric acid levels []

Secondary Outcome Measures

  1. Lowering of the fractional excretion of uric acid and blood pressure []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • • Healthy adult volunteers

  • Coronary artery disease

  • Glucose intolerance or Diabetes(a fasting blood sugar of less than 100 mg/dl as per the American Diabetes Association guidelines)

  • CHF

  • Gout

  • Lactose intolerance

  • Milk allergy

  • Women who are pregnant or lactating

  • Subjects who are on any medications except birth control pills

  • Subjects who drink more than 3 servings of beer or liquor per week.

  • Normal blood pressure ( less than 120 mmHg systolic and 80 mmHg diastolic)

  • Normal serum UA levels

  • Normal renal funcion (calculated GFR >90ml/min)

Exclusion Criteria:
  • • Coronary artery disease

  • Glucose intolerance or Diabetes(a fasting blood sugar of less than 100 mg/dl as per the American Diabetes Association guidelines)

  • CHF

  • Gout

  • Lactose intolerance

  • Milk allergy

  • Women who are pregnant or lactating

  • Subjects who are on any medications except birth control pills

  • Subjects who drink more than 3 servings of beer or liquor per week

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Icahn School of Medicine at Mount Sinai

Investigators

  • Principal Investigator: Mohammed A Rafey, MD, Icahn School of Medicine at Mount Sinai

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00474396
Other Study ID Numbers:
  • 04-1094
First Posted:
May 16, 2007
Last Update Posted:
May 16, 2007
Last Verified:
May 1, 2007
Keywords provided by , ,

Study Results

No Results Posted as of May 16, 2007